Evidence Report in Solid Organ Transplant Patients: June 2008 Expert Access Presentation

Evidence Report on the Utility of
Monitoring Mycophenolic Acid in Solid Organ Transplant Patients

This presentation is a review of the Agency for Healthcare Research and Quality’s Evidence Report on the Utility of Monitoring Mycophenolic Acid in Solid Organ Transplant Patients. The following questions were systematically addressed in the report via literature review.

  1. What is the evidence that monitoring mycophenolic acid (MPA) in patients who receive a solid organ transplant results in a lowered incidence of transplant rejections and/or adverse events compared to patients who are not monitored?
  2. Does that incidence differ by:

a. MPA dose and dose frequency?
b. Type of MPA (mycophenolate mofetil, enteric coated mycopheolate sodium)?
c. Total versus free MPA, albumin, genetic differences, or metabolites?
d. Assay method?
e. Analytical method of MPA monitoring?
f. Age, gender, ethnicity, concomitant use of calcineurin inhibitors or other medications, or comorbidity?

  1. What is the short and long term cost effectiveness of avoiding acute rejection due to MPA monitoring?

In addition, a brief review of the data supporting mycophenolic acid therapy is presented, along with a quality assessment of the abstracted studies.

Click here to view the Evidence Report in its entirety. 

Page Access: